Targeting mast cells in endometriosis with Janus kinase 3 inhibitor, JANEX-1

American Journal of Reproductive Immunology

Volumn 58, Issue 2, 2007, Pages 75-97

  D'cruz, Osmond J ^a,b,c   Uckun, Fatih M ^a,b,c  

^a Paradigm Pharmaceuticals   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

^c Parker Hughes Clinics   (United States)

Author keywords

Endometriosis; JAK3 inhibitors; Mast cells; Pelvic pain

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANALGESIC AGENT; ANTIESTROGEN; ANTIGESTAGEN; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; CYTOKINE; DANAZOL; ETORICOXIB; FOLLITROPIN; GONADORELIN; IBUPROFEN; IMMUNOGLOBULIN E RECEPTOR; IMMUNOMODULATING AGENT; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LEUPRORELIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE; METHOTREXATE; NAFARELIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; ROFECOXIB; STAT PROTEIN; UNINDEXED DRUG; VALDECOXIB;

ABDOMINAL BLEEDING; ABDOMINAL MASS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BONE DEMINERALIZATION; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELLULITIS; CLINICAL TRIAL; COLITIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENITAL BLEEDING; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERALGESIA; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; KIDNEY DISEASE; MAST CELL; MAST CELL DEGRANULATION; MENOPAUSAL SYNDROME; MENTAL INSTABILITY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PELVIS PAIN SYNDROME; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; SUNBURN; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VIRILIZATION; WEIGHT GAIN;

ENDOMETRIOSIS; FEMALE; HUMANS; INFERTILITY, FEMALE; JANUS KINASE 3; MAST CELLS; QUINAZOLINES;

EID: 34547108847     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2007.00502.x     Document Type: Review

References (274)

1. Podgaec S, Abrao MS, Dias JA Jr, Rizzo LV, de Oliveira RM, Baracat EC: Endometriosis: An inflammatory disease with a Th2 immune response component. Hum Reprod 2007; 22: 1373-1379.
2. Braun DP,ADmowski WP: Endometriosis: abnormal endometrium and dysfunctional immune response. Curr Opin Obstet Gynecol 1998; 10: 365-369.
3. Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, Wilcox LS: Hysterectomy surveillance - United States, 1980-1993. MMWR CDC Surveill Summ 1997; 46: 1-15.
4. Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL: Economic burden of endometriosis. Fertil Steril 2006; 86: 1561-7152.
5. Cramer DW, Missmer SA: The epidemiology of endometriosis. Ann N Y Acad Sci 2002; 955: 11-22.
6. Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ: Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 1991; 55: 759-765.
7. Rice VM: Conventional medical therapies for endometriosis. Ann N Y Acad Sci 2002; 955: 343-352.
8. Valle RF,TSicarra JJ: Endometriosis: treatment strategies. Ann NY Acad Sci 2003; 997: 229-239.
9. Nothnick WB, D'Hooghe TM: MedicNl management of endometriosis: novel targets and approaches towards the development of future treatment regimes. Gynecol Obstet Invest 2003; 55: 189-198.
10. Mahutte NG, Arici A: Medical management of endometriosis-associated pain. Obstet Gynecol Clin North Am 2003; 30: 133-150.
11. Mounsey AL, Wilgus A, Slawson DC: Diagnosis and management of endometriosis. Am Fam Physician 2006; 74: 594-600.
12. Crosignani P, Olive D, Bergqvist A, Luciano A: Advances in the management of endometriosis: An update for clinicians. Hum Reprod Update 2006; 12: 179-189.
13. Sutton CJ, Ewen SP, Whitelaw N, Haines P: Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994; 62: 696-700.
14. Brosens IA: Endometriosis. Current issues in diagnosis and medical management. J Reprod Med 1998; 43: 281-286.
15. Spaczynski RZ, Duleba AJ: Diagnosis of endometriosis. Semin Reprod Med 2003; 21: 193-208.
16. Brosens I, Puttemans P, Campo R, Gordts S, Brosens J: Non-invasive methods of diagnosis of endometriosis. Curr Opin Obstet Gynecol 2003; 15: 519-522.
17. Chapron C, Chopin N, Borghese B, Foulot H, Dousset B, Vacher-Lavenu MC, Vieira M, Hasan W, Bricou A: Deeply infiltrating endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod 2006; 21: 1839-1845.
18. Bazot M, Darai E, Hourani R, Thomassin I, Cortez A, Uzan S, Buy JN: Deep pelvic endometriosis: MR imaging for diagnosis and prediction of extension of disease. Radiology 2004; 232: 379-389.
19. Kinkel K, Frei KA, Balleyguier C, Chapron C: Diagnosis of endometriosis with imaging: A review. Eur Radiol 2006; 16: 285-298.
20. Ohba T, Mizutani H, Maeda T, Matsuura K, Okamura H: Evaluation of endometriosis in uterosacral ligaments by transrectal ultrasonography. Hum Reprod 1996; 11: 2014-2017.
21. Benagiano G, Brosens I: History of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 449-463.
22. American Fertility Society: Revised American Fertility Society classification of endometriosis 1985. Fertil Steril 1985; 43: 351-352.
23. Mahmood TA, Templeton AA, Thomson L, Fraser C: Menstrual symptoms in women with pelvic endometriosis. Br J Obstet Gynaecol 1991; 98: 558-563.
24. Rock JA: Endometriosis and pelvic pain. Fertil Steril 1993; 60: 950-951.
25. Fauconnier A, Chapron C, Dubuisson JB, Vieira M, Dousset B, Breart G: Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis. Fertil Steril 2002; 78: 719-726.
26. Fauconnier A, Chapron C: Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum Reprod Update 2005; 11: 595-606.
27. Fujishita A, Khan KN, Masuzaki H, Ishimaru T: Influence of pelvic endometriosis and ovarian endometrioma on fertility. Gynecol Obstet Invest 2002; 53 (Suppl. 1): 40-45.
28. Quinn M, Armstrong G: Uterine nerve fibre proliferation in advanced endometriosis. J Obstet Gynaecol 2004; 24: 932-933.
29. Milingos S, Protopapas A, Kallipolitis G, Drakakis P, Makrigiannakis A, Liapi A, Milingos D, Antsaklis A, Michalas S: Laparoscopic evaluation of infertile patients with chronic pelvic pain. Reprod Biomed Online 2006; 12: 347-353.
30. Husby GK, Haugen RS, Moen MH: Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 2003; 82: 649-653.
31. Janne O, Kauppila A, Kokko E, Lantto T, Ronnberg L, Vihko R: Estrogen and progestin receptors in endometriosis lesions: Comparison with endometrial tissue. Am J Obstet Gynecol 1981; 141: 562-566.
32. Murphy AA: Clinical aspects of endometriosis. Ann N Y Acad Sci 2002; 955: 1-10.
33. Bergqvist A: Extragenital endometriosis. Eur J Surg 1992; 158: 7-12.
34. Karlsson B, Granberg S, Hellberg P, Wikland M: Comparative study of transvaginal sonography and hysteroscopy for the detection of pathologic endometrial lesions in women with postmenopausal bleeding. J Ultrasound Med 1994; 13: 757-762.
35. Brosens IA: Endometriosis - a disease because it is characterized by bleeding. Am J Obstet Gynecol 1997; 176: 263-267.
36. Wardle PG, Mitchell JD, McLaughlin EA, Ray BD, McDermott A, Hull MG: Endometriosis and ovulatory disorder: Reduced fertilization in vitro compared with tubal and unexplained infertility. Lancet 1985; 2: 236-239.
37. Liu DT, HItchcock A: Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol 1986; 93: 859-862.
38. Szendei G, Hernadi Z, Devenyi N, Csapo Z: Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol 2005; 21: 93-100.
39. Ripps BA, Martin DC: Correlation of focal pelvic tenderness with implant dimension and stage of endometriosis. J Reprod Fertil 1992; 37: 620-624.
40. Jabbour HN, Sales KJ: Prostaglandin receptor signalling and function in human endometrial pathology. Trends Endocrinol Metab 2004; 1: 398-404.
41. Ripps BA, Martin DC: Endometriosis and chronic pelvic pain. Obstet Gynecol Clin North Am 1993; 20: 709-717.
42. Wu MH, ShDji Y, Chuang PC, Tsai SJ: Endometriosis: disease pathophysiology and the role of prostaglandins. Expert Rev Mol Med 2007; 9: 1-2.
43. Sales KJ, Jabbour HN: Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 2003; 126: 559-567.
44. Nichols TR, Lamb K, Arkins JA: The association of atopic diseases with endometriosis. Ann Allergy 1987; 59: 360-363.
45. Ferrero S, Petrera P, Colombo BM, Navaratnarajah R, Parisi M, Anserini P, Remorgida V, Ragni N: Asthma in women with endometriosis. Hum Reprod 2005; 20: 3514-3517.
46. Olive DL, Schwartz LB: Endometriosis. N Engl J Med 1993; 328: 1759-1769.
47. Meyer R: Zur Frage de heterotopen Epithelwucherung, insbesondere des Peritonealepithels und in die Ovarien. Virch Arch Path Anat Phys 1924; 250: 595-610.
48. Gruenwald P: Origin of endometriosis from mesenchyme of the coelomic walls. Am J Obstet Gynecol 1942; 44: 470-474.
49. Donnez J, Nisolle M, Casanas-Roux F, Bassil S, Anaf V: Rectovaginal septum, endometriosis or adenomyosis: Laparascopic management in a series of 231 patients. Hum Reprod 1995; 10: 630-635.
50. Sampson JA: Peritoneal endometriosis due to menstrual dissemination of the endometrial tissue into the peritoneal cavitiy. Am J Obstet Gynecol 1927; 14: 422-469.
51. Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM: Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 1984; 64: 151-154.
52. Joseph J, Sahn SA: ThoracicNendometriosis syndrome: new observations from an analysis of 110 cases. Am J Med 1996; 100: 164-170.
53. Kirschner PA: Porous diaphragm syndromes. Chest Surg Clin North Am 1998; 8: 448-472.
54. Simpson JL, Bischoff FZ: Heritability and molecular genetic studies of endometriosis. Ann N Y Acad Sci 2002; 955: 239-251.
55. Thomas EJ, Lenton EA, Cooke ID: Follicle growth patterns and endocrinological abnormalities in infertile women with minor degrees of endometriosis. Br J Obstet Gynaecol 1986; 93: 852-858.
56. Dmowski WP, Steele RW, Baker GF: Deficient cellular immunity in endometriosis. Am J Obstet Gynecol 1981; 141: 377-383.
57. Vercellini P, Aimi G, De Giorgi O, Maddalena S, Carinelli S, Crosignani PG: Is cystic ovarian endometriosis an asymmetric disease? Br J Obstet Gynaecol 1998; 105: 1018-1021.
58. Zeyneloglu HB, Arici A, Olive DL: Environmental toxins and endometriosis. Obstet Gynecol Clin North Am 1997; 24: 307-329.
59. Wild RA, Shivers CA: Antiendometrial antibodies in patients with endometriosis. Am J Reprod Immunol Microbiol 1985; 8: 84-86.
60. Gleicher N, el-Roeiy A, Confino E, Friberg J: Is endometriosis an autoimmune disease? Obstet Gynecol 1987; 70: 115-122.
61. D'Cruz OJ, Wild RA: Evaluation of endometrial tissue specific complement activation in women with endometriosis. Fertil Steril 1992; 57: 787-795.
62. Oral E, Olive DL, Arici A: The peritoneal environment in endometriosis. Hum Reprod Update 1996; 2: 385-398.
63. D'Cruz OJ, Wild RA, Haas GG Jr, Reichlin M: Antibodies to carbonic anhydrase in endometriosis: Prevalence, specificity, and relationship to clinical and laboratory parameters. Fertil Steril 1996; 66: 547-556.
64. D'Hooghe TM, Xiao L, Hill JA: Cytokine profiles in autologous peritoneal fluid and peripheral blood of women with deep and superficial endometriosis. Arch Gynecol Obstet 2001; 265: 40-44.
65. Iwabe T, Harada T, Terakawa N: Role of cytokines in endometriosis-associated infertility. Gynecol Obstet Invest 2002; 53: 19-25.
66. Szyllo K, Tchorzewski H, Banasik M, Glowacka E, Lewkowicz P, Kamer-Bartosinska A: The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis. Mediators Inflamm 2003; 12: 131-138.
67. Markowska J, Kowalska M, Gogacz M, Lubin J, Markowski M, Kaminska J: Cytokines and endometriosis. Clin Exp Obstet Gynecol 2004; 31: 269-270.
68. Garzetti GG, Ciavattini A, Provinciali M, Muzzioli M, Di Stefano G, Fabris N: Natural killer activity in stage III and IV endometriosis: impaired cytotoxicity and retained lymphokine responsiveness of natural killer cells. Gynecol Endocrinol 1995; 9: 125-130.
69. Jones RK, Bulmer JN, Searle RF: Phenotypic and functional studies of leukocytes in human endometrium and endometriosis. Hum Reprod Update 1998; 4: 702-709.
70. Matarese G, De Placido G, Nikas Y, Alviggi C: Pathogenesis of endometriosis: Natural immunity dysfunction or autoimmune disease? Trends Mol Med 2003; 9: 223-228.
71. Calhaz-Jorge C, Costa AP, Santos MC, Palma-Carlos ML: Soluble intercellular adhesion molecule 1 in the peritoneal fluid of patients with endometriosis correlates with the extension of peritoneal implants. Eur J Obstet Gynecol Reprod Biol 2003; 106: 170-174.
72. Vigano P, Infantino M, Lattuada D, Lauletta R, Ponti E, Somigliana E, Vignali M, DiBlasio AM: Intercellular adhesion molecule-1 (ICAM-1) gene polymorphisms in endometriosis. Mol Hum Reprod 2003; 9: 47-52.
73. Lebovic DI, Chao VA, Taylor RN: Peritoneal macrophages induce RANTES (regulated on activation, normal T cell expressed and secreted) chemokine gene transcription in endometrial stromal cells. J Clin Endocrinol Metab 2004; 89: 1397-1401.
74. Ulukus M, Arici A: Immunology of endometriosis. Minerva Ginecol 2005; 57: 237-248.
75. Morin M, Bellehumeur C, Therriault MJ, Metz C, Maheux R, Akoum A: Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis. Fertil Steril 2005; 83: 865-872.
76. Richter ON, Dorn C, Rosing B, Flaskamp C, Ulrich U: Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis. Arch Gynecol Obstet 2005; 271: 143-147.
77. Kats R, Collette T, Metz CN, Akoum A: Marked elevation of macrophage migration inhibitory factor in the peritoneal fluid of women with endometriosis. Fertil Steril 2002; 78: 69-76.
78. Khorram O, Taylor RN, Ryan IP, Schall TJ, Landers DV: Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis. Am J Obstet Gynecol 1993; 169: 1545-1549.
79. Arici A, Oral E, Attar E, Tazuke SI, Olive DL: Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells. Fertil Steril 1997; 67: 1065-1072.
80. Cheong YC, Shelton JB, Laird SM, Richmond M, Kudesia G, Li TC, Ledger WL: IL-1, IL-6 and TNF-alpha concentrations in the peritoneal fluid of women with pelvic adhesions. Hum Reprod 2002; 17: 69-75.
81. Suzumori N, Katano K, Suzumori K: Peritoneal fluid concentrations of epithelial neutrophil-activating peptide-78 correlate with the severity of endometriosis. Fertil Steril 2004; 81: 305-308.
82. Khan KN, Masuzaki H, Fujishita A, Kitajima M, Hiraki K, Sekine I, Matsuyama T, Ishimaru T: Interleukin-6- and tumour necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cells and its involvement in the growth of endometriosis. Hum Reprod 2005; 20: 2715-2723.
83. Harada T, Enatsu A, Mitsunari M, Nagano Y, Ito M, Tsudo T, Taniguchi F, Iwabe T, Tanikawa M, Terakawa N: Role of cytokines in progression of endometriosis. Gynecol Obstet Invest 1999; 47: 34-39.
84. Hirota Y, Osuga Y, Hirata T, Harada M, Morimoto C, Yoshino O, Koga K, Yano T, Tsutsumi O, Taketani Y: Activation of protease-activated receptor 2 stimulates proliferation and interleukin (IL)-6 and IL-8 secretion of endometriotic stromal cells. Hum Reprod 2005; 20: 3547-3553.
85. Capellino S, Montagna P, Villaggio B, Sulli A, Soldano S, Ferrero S, Remorgida V, Cutolo M: Role of estrogens in inflammatory response: expression of estrogen receptors in peritoneal fluid macrophages from endometriosis. Ann N Y Acad Sci 2006; 1069: 263-267.
86. Yih S, Katabuchi H, Araki M, Matsuura K, Takeya M, Takahashi K, Okamura H: Expression of monocyte chemoattractant protein-1 in peritoneal endometriotic cells. Virchows Arch 2001; 438: 70-77.
87. Hudelist G, Lass H, Keckstein J, Walter I, Wieser F, Wenzl R, Mueller R, Czerwenka K, Kubista E, Singer CF: Interleukin 1alpha and tissue-lytic matrix metalloproteinase-1 are elevated in ectopic endometrium of patients with endometriosis. Hum Reprod 2005; 20: 1695-1701.
88. Koga K, Osuga Y, Yoshino O, Hirota Y, Yano T, Tsutsumi O, Taketani Y: Elevated interleukin-16 levels in the peritoneal fluid of women with endometriosis may be a mechanism for inflammatory reactions associated with endometriosis. Fertil Steril 2005; 83: 878-882.
89. Taylor RN, Lebovic DI, Mueller MD: Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002; 955: 89-100.
90. Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, Barros H: Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 2006; 273: 227-231.
91. Maas JW, Calhaz-Jorge C, ter Riet G, Dunselman GA, de Goeij AF, Struijker-Boudier HA: Tumor necrosis factor-alpha but not interleukin-1 beta or interleukin-8 concentrations correlate with angiogenic activity of peritoneal fluid from patients with minimal to mild endometriosis. Fertil Steril 2001; 75: 180-185.
92. Ishimaru T, Khan KN, Fujishita A, Kitajima M, Masuzaki H: Hepatocyte growth factor may be involved in cellular changes to the peritoneal mesothelium adjacent to pelvic endometriosis. Fertil Steril 2004; 81: 810-818.
93. Yoshino O, Osuga Y, Koga K, Hirota Y, Tsutsumi O, Yano T, Morita Y, Momoeda M, Fujiwara T, Kugu K, Taketani Y: Concentrations of interferon-gamma-induced protein-10 (IP-10), an antiangiogenic substance, are decreased in peritoneal fluid of women with advanced endometriosis. Am J Reprod Immunol 2003; 50: 60-65.
94. Nishida M, Nasu K, Ueda T, Fukuda J, Takai N, Miyakawa I: Endometriotic cells are resistant to interferon-gamma-induced cell growth inhibition and apoptosis: A possible mechanism involved in the pathogenesis of endometriosis. Mol Hum Reprod 2005; 11: 29-34.
95. Vernet-Tomas Mdel M, Perez-Ares CT, Verdu N, Molinero JL, Fernandez-Figueras MT, Carreras R: The endometria of patients with endometriosis show higher expression of class I human leukocyte antigen than the endometria of healthy women. Fertil Steril 2006; 85: 78-83.
96. Gleicher N: The role of humoral immunity in endometriosis. Acta Obstet Gynecol Scand Suppl 1994; 159: 15-17.
97. Wild RA, Hirisave V, Podczaski ES, Coulam C, Shivers CA, Satyaswaroop PG: Autoantibodies associated with endomCtriosis: can their detection predict presence of the disease? Obstet Gynecol 1991; 77: 927-931.
98. Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P: High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: A survey analysis. Hum Reprod 2002; 17: 2715-2724.
99. Seery JP: Endometriosis associated with defective handling of apoptotic cells in the female genital tract is a major cause of autoimmune disease in women. Med Hypotheses 2006; 66: 945-949.
100. Somigliana E, Vigano P, Vignali M: Endometriosis and unexplained recurrent spontaneous abortion: Pathological states resulting from aberrant modulation of natural killer cell function? Hum Reprod Update 1999; 5: 40-51.
101. Tomassetti C, Meuleman C, Pexsters A, Mihalyi A, Kyama C, Simsa P, D'Hooghe TM: Endometriosis, recurrent miscarriage and implantation failure: Is there an immunological link? Reprod Biomed Online 2006; 13: 58-64.
102. Xu H, Schultze-Mosgau A, Agic A, Diedrich K, Taylor RN, Hornung D: Regulated upon activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein 1 in follicular fluid accumulate differentially in patients with and without endometriosis undergoing in vitro fertilization. Fertil Steril 2006; 86: 1616-1620.
103. Pizzo A, Salmeri FM, Ardita FV, Sofo V, Tripepi M, Marsico S: Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol Obstet Invest 2002; 54: 82-87.
104. Gallinelli A, Chiossi G, Giannella L, Marsella T, Genazzani AD, Volpe A: Different concentrations of interleukins in the peritoneal fluid of women with endometriosis: Relationships with lymphocyte subsets. Gynecol Endocrinol 2004; 18: 144-151.
105. Gmyrek GB, Sozanski R, Jerzak M, Chrobak A, Wickiewicz D, Skupnik A, Sieradzka U, Fortuna W, Gabrys M, Chelmonska-Soyta A: Evaluation of monocyte chemotactic protein-1 levels in peripheral blood of infertile women with endometriosis. Eur J Obstet Gynecol Reprod Biol 2005; 122: 199-205.
106. Kayisli UA, Mahutte NG, Arici A: Uterine chemokines in reproductive physiology and pathology. Am J Reprod Immunol 2002; 47: 213-221.
107. Koshiba H, Kitawaki J, Teramoto M, Kitaoka Y, Ishihara H, Obayashi H, Ohta M, Hara H, Adachi T, Honjo H: Expression of allograft inflammatory factor-1 in human eutopic endometrium and endometriosis: Possible association with progression of endometriosis. J Clin Endocrinol Metab 2005; 90: 529-537.
108. Kyama CM, Overbergh L, Debrock S, Valckx D, Vander Perre S, Meuleman C, Mihalyi A, Mwenda JM, Mathieu C, D'Hooghe TM: Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis. Fertil Steril 2006; 85: 1667-1675.
109. Lebovic DI, Mueller MD, Taylor RN: Immunobiology of endometriosis. Fertil Steril 2001; 75: 1-10.
110. Ulukus M, Cakmak H, Arici A: The role of endometrium in endometriosis. J Soc Gynecol Investig 2006; 13: 467-476.
111. Halis G, Arici A: Endometriosis and inflammation in infertility. Ann N Y Acad Sci 2004; 1034: 300-315.
112. Surrey ES, Halme J: Endometriosis as a cause of infertility. Obstet Gynecol Clin North Am 1989; 16: 79-91.
113. Brosens I, Campo R, Gordts S: Reproductive disorders affecting fertility in endometriosis. Reprod Biomed Online 2002; 4: 59-63.
114. Gomez-Torres MJ, Acien P, Campos A, Velasco I: Embryotoxicity of peritoneal fluid in women with endometriosis. Its relation with cytokines and lymphocyte populations. Hum Reprod 2002; 17: 777-781.
115. Aeby TC, Huang T, Nakayama RT: The effect of peritoneal fluid from patients with endometriosis on human sperm function in vitro. Am J Obstet Gynecol 1996; 174: 1779-1783.
116. Lea RG, Clark DA: Macrophages and migratory cells in endometrium relevant to implantation. Baillieres Clin Obstet Gynaecol 1991; 5: 25-59.
117. Guilbert L, Robertson SA, Wegmann TG: The trophoblast as an integral component of a macrophage-cytokine network. Immunol Cell Biol 1993; 71: 49-57.
118. Lu PY, OrC SJ: Endometriosis: current management. Mayo Clin Proc 1995; 7: 453-463.
119. Adamson GD: Treatment of endometriosis-associated infertility. Semin Reprod Endocrinol 1997; 15: 263-271.
120. Adamson D: Surgical management of endometriosis. Semin Reprod Med 2003; 21: 223-234.
121. Martin DC, O'Conner DT: Surgical management of endometriosis-associated pain. Obstet Gynecol Clin North Am 2003; 30: 151-162.
122. Scarselli G, Rizzello F, Cammilli F, Ginocchini L, Coccia ME: Diagnosis and treatment of endometriosis. A review. Minerva Ginecol 2005; 57: 55-78.
123. Candiani M: Current guidelines for treatment of endometriosis without laparoscopy. Drugs Today (Barc) 2005; 41 (Suppl. A): 11-15.
124. Atwal G, Du Plessis D, Armstrong G, Slade R, Quinn M: Uterine innervation after hysterectomy for chronic pelvic pain with, and without, endometriosis. Am J Obstet Gynecol 2005; 193: 1650-1655.
125. Fleisch MC, Xafis D, De Bruyne F, Hucke J, Bender HG, Dall P: Radical resection of invasive endometriosis with bowel or bladder involvement - long-term results. Eur J Obstet Gynecol Reprod Biol 2005; 123: 224-229.
126. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E: On behalf of the ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis Hum Reprod 2005; 20: 2698-2704.
127. Farquehar CM, Steiner CA: Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002; 99: 229-234.
128. Busacca M, Riparini J, Somigliana E, Oggioni G, Izzo S, Vignali M, Candiani M: Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol 2006; 195: 421-425.
129. Kikuchi I, Takeuchi H, Kitade M, Shimanuki H, Kumakiri J, Kinoshita K: Recurrence rate of endometriomas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand 2006; 85: 1120-1124.
130. Vercellini P, Fedele L, Aimi G, De Giorgi O, Consonni D, Crosignani PG: Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: The predictive value of the current classification system. Hum Reprod 2006; 21: 2679-2685.
131. Exacoustos C, Zupi E, Amadio A, Amoroso C, Szabolcs B, Romanini ME, Arduini D: Recurrence of endometriomas after laparoscopic removal: sonographic and clinical follow-up and indication for second surgery. J Minim Invasive Gynecol 2006; 13: 281-288.
132. Parazzini F, Bertulessi C, Pasini A, Rosati M, Di Stefano F, Shonauer S, Vicino M, Aguzzoli L, Trossarelli GF, Massobrio M, Bracco G, Perino A, Moroni S, Beretta P; Gruppo Italiano di Studio Endometriosis: Determinants of short term recurrence rate of endometriosis. Eur J Obstet Gynecol Reprod Biol 2005; 121: 216-219.
133. Weiss JM, Diedrich K, Ludwig M: Gonadotropin-releasing hormone antagonists: Pharmacology and clinical use in women. Treat Endocrinol 2002; 1: 281-291.
134. Donnez J, Squifflet J, Pirard C, Jadoul P, Wyns C, Smets M: The efficacy of medical and surgical treatment of endometriosis-associated infertility and pelvic pain. Gynecol Obstet Invest 2002; 54: 2-7.
135. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K: Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002; 5: 12-16.
136. Rotondi M, Labriola D, Rotondi M, Ammaturo FP, Amato G, Carella C, Izzo A, Panariello S: Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynecol Oncol 2002; 23: 523-526.
137. Winkel CA: Evaluation and management of women with endometriosis. Obstet Gynecol 2003; 102: 397-408.
138. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG: Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrheal that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80: 560-563.
139. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG: ProgestogenF for endometriosis: forward to the past. Hum Reprod Update 2003; 9: 387-396.
140. Lockhat FB, Emembolu JO, Konje JC: The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): A 3year follow-up. Hum Reprod 2005; 20: 789-793.
141. Griesinger G, Felberbaum R, Diedrich K: GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet 2005; 273: 71-78.
142. Crosignani PG, Luciano A, Ray A, Bergqvist A: Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21: 248-256.
143. Busacca M, Chiaffarino F, Candiani M, Vignali M, Bertulessi C, Oggioni G, Parazzini F: Determinants of long-term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol 2006; 195: 426-432.
144. Agarwal SK: Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density ? J Reprod Med 2002; 47: 530-534.
145. Warnock JK, Bundren JC: Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol Bull 1997; 33: 311-316.
146. Hughes E, Fedorkow D, Collins J, Vandekerckhove P: Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2003; 3: CD000155.
147. Winkel CA: A cost-effective approach to the management of endometriosis. Curr Opin Obstet Gynecol 2000; 12: 317-320.
148. Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL: Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997; 68: 860-864.
149. Gojnic M, Dugalic V, Jeremic V, Popovic N, Arsenijevic L: Endometriosis and possible malignant transformation. Eur J Gynaecol Oncol 2006; 27: 271-272.
150. Allen C, Hopewell S, Prentice A: Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005; 4: CD004753.
151. Connolly TP: Cyclooxygenase-2 inhibitors in gynecologic practice. Clin Med Res 2003; 1: 105-110.
152. Hayes EC, Rock JA: COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002; 57: 768-780.
153. Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S, Gioffre W, Mazzini M, Petraglia F: The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 116: 100-102.
154. Wu MH, Sun HS, Lin CC, Hsiao KY, Chuang PC, Pan HA, Tsai SJ: Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis. Mol Hum Reprod 2002; 8: 1103-1110.
155. Matsuzaki S, Canis M, Pouly JL, Wattiez A, Okamura K, Mage G: Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril 2004; 82: 1309-1315.
156. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR: NSAID use and progression of chronic kidney disease. Am J Med 2007; 120: 280-287.
157. Ashworth AJ: Cardiac risks with COX-2 inhibitors. CMAJ 2007; 176: 489-492.
158. Cairns JA: The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks. Can J Cardiol 2007; 23: 125-131.
159. Miller LW: Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807-818.
160. Bijlsma JW, Saag KG, Buttgereit F, Da Silva JA: Developments in glucocorticoid therapy. Rheum Dis Clin North Am 2005; 31: 1-17.
161. Vernon MW, Wilson EA: Studies on the surgical induction of endometriosis in the rat. Fertil Steril 1985; 44: 684-694.
162. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A: Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999; 72: 135-141.
163. Uchiide I, Ihara T, Sugamata M: Pathological evaluation of the rat endometriosis model. Fertil Steril 2002; 78: 782-786.
164. Berkley KJ, Dmitrieva N, Curtis KS, Papka RE: Innervation of ectopic endometrium in a rat model of endometriosis. Proc Natl Acad Sci U S A 2004; 101: 11094-11098.
165. Berkley KJ, Cason A, Jacobs H, Bradshaw H, Wood E: Vaginal hyperalgesia in a rat model of endometriosis. Neurosci Lett 2001; 306: 185-188.
166. Cummings AM, Metcalf JL: InducAion of endometriosis in mice: a new model sensitive to estrogen. Reprod Toxicol 1995; 9: 233-238.
167. Zamah NM, Dodson MG, Stephens LC, Buttram VC Jr, Besch PK, Kaufman RH: Transplantation of normal and ectopic human endometrial tissue into athymic nude mice. Am J Obstet Gynecol 1984; 149: 591-597.
168. Bergqvist A, Jeppsson S, Kullander S, Ljungberg O: Human uterine endometrium and endometriotic tissue transplanted into nude mice. Morphologic effects of various steroid hormones. Am J Pathol 1985; 121: 337-341.
169. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG: Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest 1997; 99: 2851-2857.
170. Nisolle M, Casanas-RoAx F, Donnez J: Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. Fertil Steril 2000; 74: 306-312.
171. Van Langendonckt A, Casanas-Roux F, Eggermont J, Donnez J: Characterization of iron deposition in endometriotic lesions induced in the nude mouse model. Hum Reprod 2004; 19: 1265-1271.
172. Eggermont J, Donnez J, Casanas-Roux F, Scholtes H, Van Langendonckt A: Time course of pelvic endometriotic lesion revascularization in a nude mouse model. Fertil Steril 2005; 84: 492-499.
173. Aoki D, Katsuki Y, Shimizu A, Kakinuma C, Nozawa S: Successful heterotransplantation of human endometrium in SCID mice. Obstet Gynecol 1994; 83: 220-228.
174. Awwad JT, Sayegh RA, Tao XJ, Hassan T, Awwad ST, Isaacson K: The SCID mouse: An experimental model for endometriosis. Hum Reprod 1999; 14: 3107-3111.
175. Grummer R, Schwarzer F, Bainczyk K, Hess-Stumpp H, Regidor PA, Schindler AE, Winterhager E: PVritoneal endometriosis: validation of an in-vivo model. Hum Reprod 2001; 16: 1736-1743.
176. Matsuura-Sawada R, Murakami T, Ozawa Y, Nabeshima H, Akahira J, Sato Y, Koyanagi Y, Ito M, Terada Y, Okamura K: Reproduction of menstrual changes in transplanted human endometrial tissue in immunodeficient mice. Hum Reprod 2005; 20: 1477-1484.
177. MacKenzie WF, Casey HW: Animal model of human disease. Endometriosis. Animal model: Endometriosis in rhesus monkeys. Am J Pathol 1975; 80: 341-344.
178. D'Hooghe TM, Bambra CS, Cornillie FJ, Isahakia M, Koninckx PR: Prevalence and laparoscopic appearance of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus). Biol Reprod 1991; 45: 411-416.
179. Dick EJ Jr, Hubbard GB, Martin LJ, Leland MM: Record review of baboons with histologically confirmed endometriosis in a large established colony. J Med Primatol 2003; 32: 39-47.
180. D'Hooghe TM, Bambra CS, Xiao L, Peixe K, Hill JA: Effect of menstruation and intrapelvic injection of endometrium on inflammatory parameters of peritoneal fluid in the baboon (Papio anubis and Papio cynocephalus). Am J Obstet Gynecol 2001; 184: 917-925.
181. Te Linde RW, Scott RB: Experimental endometriosis. Am J Obstet Gynecol 1950; 60: 1147-1173.
182. D'Hooghe TM, Bambra CS, Suleman MA, Dunselman GA, Evers HL, Koninckx PR: Development of a model of retrograde menstruation in baboons (Papio anubis). Fertil Steril 1994; 62: 635-638.
183. D'Hooghe TM, Bambra CS, Raeymaekers BM, De Jonge I, Lauweryns JM, Koninckx PR: Intrapelvic injection of menstrual endometrium causes endometriosis in baboons (Papio cynocephalus and Papio anubis). Am J Obstet Gynecol 1995; 173: 125-134.
184. Fazleabas AT, Brudney A, Gurates B, Chai D, Bulun S: A modified baboon model for endometriosis. Ann N Y Acad Sci 2001; 955: 308-317.
185. Fazleabas AT: A baboon model for inducing endometriosis. Methods Mol Med 2005; 121: 93-98.
186. D'Hooghe TM, Debrock S: Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Hum Reprod Update 2002; 8: 84-88.
187. Matsuzaki S, Canis M, Darcha C, Fukaya T, Yajima A, Bruhat MA: Increased mast cell density in peritoneal endometriosis compared with eutopic endometrium with endometriosis. Am J Reprod Immunol 1998; 40: 291-294.
188. Fujiwara H, Konno R, Netsu S, Sugamata M, Shibahara H, Ohwada M, Suzuki M: Localization of mast cells in endometrial cysts. Am J Reprod Immunol 2004; 51: 341-344.
189. Sugamata M, Ihara T, Uchiide I: Increase of activated mast cells in human endometriosis. Am J Reprod Immunol 2005; 53: 120-125.
190. Anaf V, Chapron C, El Nakadi I, De Moor V, Simonart T, Noel JC: Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril 2006; 86: 1336-1343.
191. Kempuraj D, Papadopoulou N, Stanford EJ, Christodoulou S, Madhappan B, Sant GR, Solage K, Adams T, Theoharides TC: Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol 2004; 52: 267-275.
192. Madhappan B, Sant GR, Solage K, Adams T, Theoharides TC: Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol 2004; 52: 267-275.
193. Konno R, Yamada-Okabe H, Fujiwara H, Uchiide I, Shibahara H, Ohwada M, Ihara T, Sugamata M, Suzuki M: Role of immunoreactions and mast cells in pathogenesis of human endometriosis-morphologic study and gene expression analysis. Hum Cell 2003; 16: 141-149.
194. Ihara T, Uchiide I, Sugamata M: Light and electron microscopic evaluation of antileukotriene therapy for experimental rat endometriosis. Fertil Steril 2004; 81: 819-823.
195. Liu T, Van Rooijen N, Tracey DJ: Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain 2000; 86: 25-32.
196. Zuo Y, Perkins NM, Tracey DJ, Geczy CL: Inflammation and hyperalgesia induced by nerve injury in the rat: A key role of mast cells. Pain 2003; 105: 467-479.
197. TheoharidAs TC: The mast cell: a neuroimmunoendocrine master player. Int J Tissue Reactions 1996; 18: 1-21.
198. Blank U, Rivera J: The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004; 25: 266-273.
199. Kambayashi T, Koretzky GA: Proximal signaling events in FcvarepsilonRI-mediated mast cell activation. J Allergy Clin Immunol 2007; 119: 544-552.
200. Sada K, Yamamura H: Protein-tyrosine kinases and adaptor proteins in FcepsilonRI-mediated signaling in mast cells. Curr Mol Med 2003; 3: 85-94.
201. Gilfillan AM, Tkaczyk C: Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006; 6: 218-230.
202. Shelburne CP, Ryan JJ: The role of Th2 cytokines in mast cell homeostasis. Immunol Rev 2001; 179: 82-93.
203. Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, Bunting KD, Ryan JJ: Stat5 expression is required for IgE-mediated mast cell function. J Immunol 2006; 177: 3421-3426.
204. Sengupta TK, Schmitt EM, Ivashkiv LB: Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc Natl Acad Sci U S A 1996; 93: 9499-9504.
205. Ihle JN, Kerr IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11: 69-74.
206. Darnell JE Jr: Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998; 18: 549-554.
207. Leonard WJ: Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 2001; 73: 271-277.
208. Imada K, Leonard WJ: The Jak-STAT pathway. Mol Immunol 2000; 37: 1-11.
209. Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K: Jaks and Stats in cytokine signaling. Stem Cells 1997; 15: 105-111.
210. Thomis DC, Berg LJ: The role of Jak3 in lymphoid development, activation, and signaling. Curr Opin Immunol 1997; 9: 541-547.
211. Malaviya R, Uckun FM: Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem Biophys Res Commun 1999; 257: 807-813.
212. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ: Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 1995; 270: 797-800.
213. Thomis DC, Aramburu J, Berg L: The Jak family tyrosine kinase Jak3 is required for IL-2 synthesis by naive/resting CD4+ T cells. J Immunol 1999; 163: 5411-5417.
214. Jabara HH, Buckley RH, Roberts JL, Lefranc G, Loiselet J, Khalil G, Geha RS: Role of JAK3 in CD40-mediated signaling. Blood 1998; 92: 2435-2440.
215. Matsumoto M, Ra C, Kawamoto K, Sato H, Itakura A, Sawada J, Ushio H, Suto H, Mitsuishi K, Hikasa Y, Matsuda H: IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J Immunol 1999; 162: 1056-1063.
216. Papageorgiou AC, Wikman LE: Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol Sci 2004; 25: 558-562.
217. Borie DC, O'Shea JJ, Changelian PS: JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004; 10: 532-541.
218. Habib T, Senadheera S, Weinberg K, Kaushansky K: The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002; 41: 8725-8731.
219. Saemann MD, Diakos C, Kelemen P, Kriehuber E, Zeyda M, Bohmig GA, Horl WH, Baumruker T, Zlabinger GJ: Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant 2003; 3: 1341-1349.
220. Saemann MD, Zeyda M, Diakos C, Szekeres A, Bohmig GA, Kelemen P, Parolini O, Stockinger H, Prieschl EE, Stulnig TM, Baumruker T, Zlabinger GJ: Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003; 75: 1864-1872.
221. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM: Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999; 5: 1569-1582.
222. Sudbeck EA, Jennissen JD, Liu XP, Uckun FM: An inhibitor of Janus kinase 3:4-(4-hydroxyphenylamino)-6, 7-dimethoxyquinazolin-1-ium chloride methanol solvate. Acta Crystallogr C 2000; 56: 1282-1283.
223. Narla RK, Liu XP, Klis D, Uckun FM: Inhibition of human glioblastoma cell adhesion and invasion by 4-(4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and and 4-(3′-bromo-4′-hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline-(WHI-P154). Clin Cancer Res 1998; 4:2463-2467.
224. Malaviya R, Zhu D, Dibirdik I, Uckun FM: Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999; 274: 27028-27038.
225. Uckun FM, Vassilev H, Qazi S, Vassilev A: Anti-inflammatory and immunosuppressive activity profile of JANEX-1 in preclinical animal models of inflammation and transplantation. Arzneimittelforschung/Drug Res 2007 (in press).
226. Cetkovic-Cvrlje M, Dragt AL, Vassilev A, Liu XP, Uckun FM: Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin Immunol 2003; 106: 213-225.
227. Cetkovic-Cvrlje M, Dragt AL, Uckun FM: Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1). Arzneimittelforschung 2003; 53: 648-654.
228. Cetkovic-Cvrlje M, Roers BA, Waurzyniak B, Liu XP, Uckun FM: Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98: 1607-1613.
229. Uckun FM, Roers BA, Waurzyniak B, Liu XP, Cetkovic-Cvrlje M: Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002; 99: 4192-4199.
230. Cetkovic-Cvrlje M, Uckun FM: Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004; 126: 821-827.
231. Wu CH, Chen TL, Chen TG, Ho WP, Chiu WT, Chen RM: Nitric oxide modulates pro- and anti-inflammatory cytokines in lipopolysaccharide-activated macrophages. J Trauma 2003; 55: 540-545.
232. Liu H, Yao YM, Yu Y, Dong N, Yin HN, Sheng ZY: Role of Janus kinase/ signal transducer and activator of transcription pathway in regulation of expression and inflammation-promoting activity of high mobility group box protein 1 in rat peritoneal macrophages. Shock 2007; 27: 55-60.
233. Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN: Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 2007; 210: 774-783.
234. Galanos C, Freudenberg MA: Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology 1993; 187: 346-356.
235. Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H: The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A 2005; 102: 13622-13627.
236. Malaviya R, Malaviya R, Uckun FM: Anti-inflammatory activity of 2,4,6-trihydroxy-alpha-p-methoxyphenyl-acetophenone (compound D-58). Dermatology 2000; 201: 337-342.
237. Kolios G, Wright KL, Jordan NJ, Leithead JB, Robertson DA, Westwick J: C-X-C and C-C chemokine expression and secretion by the human colonic epithelial cell line, HT-29: Differential effect of T lymphocyte-derived cytokines. Eur J Immunol 1999; 29: 530-536.
238. Cross A, Asher L, Seguin M, Yuan L, Kelly N, Hammack C, Sadoff J, Gemski P Jr: The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli. J Clin Invest 1995; 96: 676-686.
239. Schrier DJ, Moniot S, Gluckman MI, Gilbertsen RB: The topical anti-inflammatory effects of a topical preparation of meclofenamic acid on carrageenan-induced footpad swelling in mice. J Pharm Pharmacol 1987; 39: 57-59.
240. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R: Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997; 89: 556-566.
241. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26: 934-938.
242. Renz H, Smith HR, Henson JE, Ray BS, Irvin CG, Gelfand EW: Aerosolized antigen exposure without adjuvant causes increased IgE production and increased airway responsiveness in the mouse. J Allergy Clin Immunol 1992; 89: 1127-1138.
243. Barton BE, Jackson JV: Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993; 61: 1496-1499.
244. Chen CL, Malaviya R, Chen H, Liu XP, Uckun FM: Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131). J Chromatogr B Biomed Sci Appl 1999; 727: 205-212.
245. Uckun FM, Thoen J, Chen H, Sudbeck E, Mao C, Malaviya R, Liu XP, Chen CL: CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural basis for inactivation by regioselective O-demethylation. Drug Metab Dispos 2002; 30: 74-85.
246. Uckun FM, Ek O, Liu XP, Chen CL: In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4′hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Clin Cancer Res 1999; 5: 2954-2962.
247. Malaviya R, Chen CL, Liu XP, Uckun FM: In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131). Am J Ther 2001; 8: 35-39.
248. Nasir L, Bope ET: Management of pelvic pain from dysmenorrhea or endometriosis. J Am Board Fam Pract 2004; 17: S43-S47.
249. Harel Z: Dysmenorrhea in adolescents andEyoung adults: etiology and management. J Pediatr Adolesc Gynecol 2006; 19: 363-371.
250. Aldington S, Shirtcliffe P, Weatherall M, Beasley R: Increased risk of cardiovascular events with parecoxib/valdecoxib: A systematic review and meta-analysis. N Z Med J 2005; 118: U1755.
251. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 2006; 332: 1302-1308.
252. Chen LC, Ashcroft DM: Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials J Clin Pharm Ther 2006; 31: 565-576.
253. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R: Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J R Soc Med 2006; 99: 132-140.
254. Verbsky JW, Randolph DA, Shornick LP, Chaplin DD: Nonhematopoietic expression of Janus kinase 3 is required for efficient recruitment of Th2 lymphocytes and eosinophils in OVA-induced airway inflammation. J Immunol 2002; 168: 2475-2482.
255. Aringer M, Hofmann SR, Frucht DM, Chen M, Centola M, Morinobu A, Visconti R, Kastner DL, Smolen JS, O'Shea JJ: Characterization and analysis of the proximal Janus kinase 3 promoter. J Immunol 2003; 170: 6057-6064.
256. Wang LH, Kirken RA, Yang XY, Erwin RA, DaSilva L, Yu CR, Farrar WL: Selective disruption of interleukin 4 autocrine-regulated loop by a tyrosine kinase inhibitor restricts activity of T-helper 2 cells. Blood 2000; 95: 3816-3822.
257. Malaviya R, Chen CL, Navara C, Liu XP, Keenan M, Waurzyniak B, Uckun FM: Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′, 5′-dibromo-4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther 2000; 295: 912-926.
258. Kilic M, Kahan BD: New trends in immunosuppression. Drugs Today (Barc) 2000; 36: 395-410.
259. Nashan B: Review of T-cIll activation: impact of Janus kinase 3 inhibition. Transplantation 2003; 75: 1783-1785.
260. Conklyn M, Andresen C, Changelian P, Kudlacz E: The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004; 76: 1248-1255.
261. Podder H, Aahan BD: Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin Ther Targets 2004; 8: 613-629.
262. Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, Flanagan M, Changelian P: The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51-57.
263. Paniagua R, Si MS, Flores MG, Rousvoal G, Zhang S, Aalami O, Campbell A, Changelian PS, Reitz BA, Borie DC: Effects of JAK3 inhibition with CP-690, 550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005; 80: 1283-1292.
264. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-878.
265. Rousvoal G, Si MS, Lau M, Zhang S, Berry GJ, Flores MG, Changelian PS, Reitz BA, Borie DC: Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006; 19: 1014-1021.
266. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA: Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 99: 680-689.
267. Stepkowski SM, Nagy ZS, Wang ME, Behbod F, Erwin-Cohen R, Kahan BD, Kirken RA: PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc 2001; 33: 3272-3273.
268. Kirken RA: Targeting Jak3 for immune suppression and allograft acceptance. Transplant Proc 2001; 33: 3268-3270.
269. Coutinho E, Goncalves MT, Azadian-Boulanger G, Silva AR: Endometriosis therapy with gestrinone by oral, vaginal or parenteral administration. Contrib Gynecol Obstet 1987; 16: 227-235.
270. Igarashi M, Iizuka M, Abe Y, Ibuki Y: Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod 1998; 13: 1952-1956.
271. McGavigan CJ, Owen P: The levonorgestrel-releasing intrauterine system in modern gynaecology. Br J Hosp Med 2005; 66: 574-577.
272. Vercellini P, Vigano P, Somigliana E: The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol 2005; 17: 359-365.
273. Muzii L: Medicated intrauterine systems for treatment of endometriosis-associated pain. J Minim Invasive Gynecol 2006; 13: 535-538.
274. De Sa Rosa e Silva AC, Rosa e Silva JC, Nogueira AA, Petta CA, Abrao MS, Ferriani RA: The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertil Steril 2006; 86: 742-744.